Novocure

NASDAQ: NVCR ↗$15.48 USD~$1.5B MCAP

#Glioblastoma (GBM)#Malignant pleural mesothelioma #Non-small cell lung cancer #Pancreatic cancer #Brain metastases #Ovarian cancer

Novocure (NASDAQ: NVCR) is an oncology medical-device company pioneering Tumor Treating Fields (TTFields), a non-invasive, antimitotic therapy delivered via wearable transducer arrays. Approved for glioblastoma (Optune Gio) and malignant pleural mesothelioma, with active programs in non-small cell lung cancer, pancreatic cancer, brain metastases, and ovarian cancer.

Company Info

Sector:Medical Device / Oncology

Headquarters:Haifa, Israel (operations in Portsmouth, NH and Root, Switzerland)

Founded:2000

Website:www.novocure.com/

Upcoming Milestones & Key Dates

2026 H2

Clinical readout / Corporate strategy

LUNAR OS readout follow-up and strategic options for Optune Lua in NSCLC

2026 Q4

Clinical readout

PANOVA-3 pancreatic adenocarcinoma Phase 3 topline

Clinical Development Pipeline

Optune Gio (TTFields)

Target: Tumor Treating Fields antimitotic mechanism

Glioblastoma (newly diagnosed and recurrent)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Optune Lua (TTFields + PD-1/PD-L1 inhibitor)

Target: Tumor Treating Fields + immune checkpoint blockade

Metastatic non-small cell lung cancer after platinum failure

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TTFields + chemo

Target: Tumor Treating Fields + gemcitabine/nab-paclitaxel

Pancreatic adenocarcinoma (locally advanced)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Novocure's electric fields therapy fails key glioblastoma study ↗

Novocure's electric fields therapy fails key glioblastoma study.

Leadership Team

Frank Leonard

Chief Executive Officer

Yoram Palti, MD PhD

Founder & Chief Technology Officer

Careers & Job Openings

See all open roles

Multiple Departments

Portsmouth, NH; Haifa, Israel; Root, Switzerland

Apply Now →